<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01149694</url>
  </required_header>
  <id_info>
    <org_study_id>PG08-PUR 0210-FIM001</org_study_id>
    <secondary_id>2009-010405-36</secondary_id>
    <nct_id>NCT01149694</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Tolerability of PUR 0110 Rectal Enema in Normal Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel-Group, Single-Ascending Dose, Placebo-Controlled Safety and Tolerability Study of PUR 0110 Rectal Enema in Normal Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PurGenesis Technologies Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PurGenesis Technologies Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-man study of a novel investigational botanical drug complex, PUR 0110&#xD;
      rectal enema, that has been shown to have potent anti-inflammatory, antioxidant and&#xD;
      immunomodulatory effects following in vitro and in vivo pharmacology studies, to assess the&#xD;
      safety and tolerability of sequential single-ascending doses in normal healthy volunteers and&#xD;
      to determine the maximum tolerated dose (MTD). As a tertiary objective, the study will also&#xD;
      investigate the presence of specific pharmacokinetic markers following the administration of&#xD;
      single-dose PUR 0110 at each dose level.&#xD;
&#xD;
      The study is designed as a single-center, randomized, double-blind, parallel-group,&#xD;
      sequential single-ascending dose, placebo-controlled safety, tolerability and pharmacokinetic&#xD;
      study of PUR 0110 rectal enema in 24 normal healthy male volunteers. Eligible subjects will&#xD;
      be randomly assigned to 4 Cohorts of 6 subjects each to receive active drug (PUR 0110 Enema)&#xD;
      or placebo enema as follows: 187.5 mg/60 g - Cohort 1, 375 mg/60 g - Cohort 2, 750 mg/60 g -&#xD;
      Cohort 3 or 1500 mg/60 g - Cohort 4. Within each Cohort, subjects will be randomized in a 2:1&#xD;
      ratio to receive either active treatment (PUR 0110 enema; n = 4) or placebo enema (n = 2).&#xD;
      Each subject will receive only 1 dose of assigned study medication and dosing of subjects&#xD;
      within each cohort will also be by sequential inclusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Flexible sigmoidoscopy will be performed during the Screening Period within 72 to 48 hours&#xD;
      pre-dose and within 9 +/- 1 hours post-dosing to visually examine the colonic mucosa for any&#xD;
      signs of local toxicity and grade it as normal/abnormal; and 3 pinch biopsies will be&#xD;
      obtained at each endoscopy at about the same level in the colon (&lt;50 cm from the anal verge)&#xD;
      for histology. At the baseline flexible sigmoidoscopy, subjects must have normal colonic and&#xD;
      rectal mucosa (i.e., no bleeding, inflammation, edema, ulceration or other abnormal finding)&#xD;
      to be included in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, nature and severity of adverse events and abnormal clinical laboratory test results</measure>
    <time_frame>After single-ascending doses</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>After single-ascending doses</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile and parameters - if specific pharmacokinetic markers are successfully identified</measure>
    <time_frame>After single-ascending doses</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PUR 0110 Rectal Enema or Placebo Enema</intervention_name>
    <description>187.5 mg/60 g</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>PUR 0110 Enema</other_name>
    <other_name>PUR 0110</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PUR 0110 Rectal Enema or Placebo Enema</intervention_name>
    <description>375 mg/60 g</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>PUR 0110 Enema</other_name>
    <other_name>PUR 0110</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PUR 0110 Rectal Enema or Placebo Enema</intervention_name>
    <description>750 mg/60 g</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>PUR 0110 Enema</other_name>
    <other_name>PUR 0110</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PUR 0110 Rectal Enema or Placebo Enema</intervention_name>
    <description>1500 mg/60 g</description>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>PUR 0110 Enema</other_name>
    <other_name>PUR 0110</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult non-smoking male volunteers between the ages of 18 to 55 years,&#xD;
             inclusive.&#xD;
&#xD;
          -  Must provide a voluntary written informed consent prior to initiation of screening,&#xD;
             must be capable of following the verbal and written study instructions, and be able to&#xD;
             commit to any confinements and return visits during the entire period of the study.&#xD;
&#xD;
          -  Must have a body mass index (BMI) that is within 18 to 30 kg/m2 on the BMI Chart.&#xD;
&#xD;
          -  Must have a normal digital rectal examination at screening.&#xD;
&#xD;
          -  Must have normal colonic and rectal mucosa at the baseline flexible sigmoidoscopy&#xD;
             (i.e., no bleeding, inflammation, edema, ulceration or other abnormal finding).&#xD;
&#xD;
          -  Must have no clinically significant abnormal findings in their medical history,&#xD;
             physical examination or clinical laboratory test results.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of clinically significant cardiovascular, pulmonary, hepatic,&#xD;
             renal, hematological, gastrointestinal, endocrine, immunologic, dermatological,&#xD;
             neurological, or psychiatric disease.&#xD;
&#xD;
          -  History of allergic reaction or hypersensitivity to spinach, spinach tablet, spinach&#xD;
             powder or spinach extract; and to latex, molds and mushrooms.&#xD;
&#xD;
          -  Subjects with abnormal digital rectal examination at screening&#xD;
&#xD;
          -  Subjects with abnormal colonic and rectal mucosa at the baseline flexible&#xD;
             sigmoidoscopy i.e., have bleeding, inflammation, edema or ulceration or other abnormal&#xD;
             finding.&#xD;
&#xD;
          -  Subjects who used NSAIDs within 14 days prior to dosing.&#xD;
&#xD;
          -  History of pseudoallergic hypersensitivity to the food color additives, tartrazine&#xD;
             (E102) and sunset yellow (E110), allergic asthma, aspirin intolerance, and severe or&#xD;
             multiple allergies.&#xD;
&#xD;
          -  History of gout, pseudogout or hyperuricemia.&#xD;
&#xD;
          -  History of kidney stones.&#xD;
&#xD;
          -  Past medical history of significant colonic surgery, except for benign polyp removal.&#xD;
&#xD;
          -  Subjects with anatomical abnormalities of the colon, e.g., short bowel or other&#xD;
             abnormalities.&#xD;
&#xD;
          -  Subjects with a history of rectal bleeding, passage of mucus rectally, and irregular&#xD;
             bowel habits, e.g., frequent diarrhea or constipation.&#xD;
&#xD;
          -  Subjects with internal or external hemorrhoids.&#xD;
&#xD;
          -  History or presence of alcoholism or drug abuse within the past 2 years.&#xD;
&#xD;
          -  Subjects with a current history of smoking. If a former smoker, must have stopped&#xD;
             smoking for at least 3 months to qualify for study entry.&#xD;
&#xD;
          -  Subjects who tested positive at screening for HIV, HbsAg or HCV.&#xD;
&#xD;
          -  Subjects who used any prescription medications within 14 days prior to dosing.&#xD;
&#xD;
          -  Subjects who used any rectal enema or laxative within 7 days prior to dosing.&#xD;
&#xD;
          -  Subjects who used any over-the-counter (OTC) medications within 7 days prior to&#xD;
             dosing.&#xD;
&#xD;
          -  Subjects who have made a donation of blood or blood products (with the exception of&#xD;
             plasma as noted below) within 56 days prior to dosing.&#xD;
&#xD;
          -  Subjects who have made a plasma donation within 7 days prior to dosing.&#xD;
&#xD;
          -  Subjects with hemoglobin less than 14.0 g/dl.&#xD;
&#xD;
          -  Subjects who participated in another clinical trial within 28 days prior to dosing.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theophilus J Gana, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>PurGenesis Technologies Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergej Berger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FOCUS Clinical Drug Development GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FOCUS Clinical Drug Development GmbH Phase 1 Clinic</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>June 22, 2010</study_first_submitted>
  <study_first_submitted_qc>June 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2010</study_first_posted>
  <last_update_submitted>June 23, 2010</last_update_submitted>
  <last_update_submitted_qc>June 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>André P. Boulet, PhD / President &amp; Chief Operating Officer</name_title>
    <organization>PurGenesis Technologies, Inc.</organization>
  </responsible_party>
  <keyword>PurGenesis Technologies Inc.</keyword>
  <keyword>PUR 0110 rectal enema</keyword>
  <keyword>Ulcerative colitis</keyword>
  <keyword>Distal</keyword>
  <keyword>Normal healthy volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

